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Digoxin is a valuable drug for a variety of cardiovascular dis-
orders but is known to have a low margin of safety. While digoxin is 
used in pediatric patients for several cardiac conditions,"'" there is 
2 
some controversy over the most appropriate dose and dosage regimen. 
These are based on presumed differences in digoxin disposition and dose 
1 2 
response relationships in infants and children as compared to adults. ' 
Two basic differences exist in the use of digoxin in children and 
adults. Children receive higher daily doses (based on body weight) 
and commonly receive the drug as two, rather than one, daily dose. 
Sensitivity Studies 
The basis for the age related differences in sensitivity to digoxin 
apparently involves several factors. Cardiac glycosides bind to and 
inhibit the transport enzyme sodium-potassium adenosine triphosphatase 
(Na-K ATPase) in different tissues. The degree of this binding may 
be age related. Miller and Gilliland demonstrated that median myo-
cardial Na-K ATPase concentration was significantly greater in fetal 
and newborn puppies than in mature dogs, which may be an explanation 
3 
for the higher digoxin concentration in the heart of the newborn. 
Postmortem concentrations of digoxin in ventricular and atrial 
tissues of infants (up to 12 months of age) are much higher than those 
4 
in adults. However, an analysis of tissues taken postmortem from 
2 
both infants and adults showed the same relative distribution in in-
fants and adults (choroid plexus > ventricular myocardium > kidney > 
liver > skeletal muscle).^ A lower concentration is found in the 
2 5 
blood. ' The average digoxin concentration in infants' ventricular 
myocardium was 190 ng/g of body weight in contrast to 70 ng/g of body 
weight in older children with ratios of ventricular myocardium to 
4 
plasma concentrations of 99:1 in infants and 114:1 in older children. 
Such data support the theory that myocardial tissue shows greater 
affinity for digoxin but decreased sensitivity in pediatric as compared 
to adult patients. 
Dose response curves obtained with neonatal myocardium are shifted 
to the right of those generated in adult rabbits.^ That is, a larger 
dose is required to induce the same response in newborn as in adult 
rabbits. 
Efficacy Studies 
Levy used systolic time intervals as a measure of digoxin effect 
on cardiac contractility in neonates (up to one month of age) and in-
fants. He observed satisfactory responses with much lower loading 
doses than those conventionally used.^ Instead of 80 mcg/kg, he used 
20-30 mcg/kg and concluded that higher dosages were unwarranted and 
produced no further changes in preejection period or ejection time.^ 
8 9 
This finding was supported in the reports of Nyberg and Neutze, 
which showed adequate positive inotropic effect at serum digoxin con-
centrations of 1.4 to 2.6 ng/ml, at doses of 18 and 22 mcg/kg/day, 
respectively. 
Toxicity Studies 
While the results of many clinical studies suggest that infants 
and young children can tolerate higher doses of digoxin per unit body 
weight than adults, 5' 8' 1 0 - 1 6 this finding was not duplicated by others. 
Hayes15 studied 31 infants, 1 to 11 months of age, who received main-
tenance doses of 14 to 28 mcg/kg/day, 33 children 2 to 14 years of age 
who received maintenance doses of 10 to 17 mcg/kg/day in younger 
children (under the age of five years) while the older children were 
given 6 to 10 mcg/kg/day and 24 adults who received maintenance doses of 
1.3 to 11.5 mcg/kg/day. These doses produced mean serum digoxin concen-
trations of 2.8 ± 1.9 ng/ml, 1.3 ± 0.4 ng/ml and 1.3 ± 0.6 ng/ml, 
respectively. Five infants, ten children and four adults manifested 
arrhythmias compatible with digoxin toxicity. The mean serum con-
centrations in those patients were 4.4 ng/ml, 3.4 ng/ml, and 2.9 
ng/ml, respectively. Halkin1^ studied 34 patients ranging in age from 
one week to two years. All patients who manifested symptoms of digoxin 
intoxication were less than one year of age. Thirteen of 34 patients 
had serum digoxin concentrations higher than 2 ng/ml and four of the 13 
18 
had signs of toxicity according to the criteria of Beller et al 
(appearance of specific electrocardiogram findings such as: premature 
ventricular contractions, ventricular bigeminy, A-V escape rhythm, A-V 
dissociation, and Mobitz Type I conduction disturbance). These results 
support the theory that digoxin serum concentrations higher than 2 ng/ml 
which are generally considered dangerous in adults but which are com-
monly considered safe in children can cause increased toxicity in 
pediatric patients.1^ 
Pharmacokinetics 
The biopharmaceutics and pharmacokinetics of digoxin in pediatric 
patients have been studied. A number of investigators have found that 
infants receiving oral maintenance therapy absorbed the drug as well 
as adults, and that the time to reach peak blood concentrations varied 
i . o i- 1,2,6,12,19 from 1 to 3 hours. 
The mean apparent volume of distribution (Vd) of digoxin has been 
shown to vary between neonates, infants and adults. Neonates and in-
fants have a larger Vd than adults (9 vs 6 1/kg, respectively). The 
reason for this difference is unclear, but might be attributable to 
greater tissue binding and to age-related differences in body compo-
sition (extracellular fluid volume and ratio of tissue weight/body 
2 10 20 
weight). ' ' The distribution of digoxin includes its excretion 
21 
into saliva. Huffman found that there was significant correlation 
between the serum and saliva levels but other investigators' data 
did not support this conclusion.^>23,24 
Studies in adults have shown that digoxin is eliminated mainly 
unchanged through the kidney by glomerular filtration. The percentage 
of various metabolites (non-renal elimination) excreted in the urine 
by patients with normal hepatic and renal function is 12 to 18 percent 
in both pediatric and adult populations. The total body elimination 
half-life (t^) in neonates ranges from 20 to 60 hours with the mean 
13 20 
being approximately 35 hours. ' The t% in infants ranges from 15 
20 25 
to 33 hours with a mean of 20 hours. ' In children, it ranges from 
6 13 
17 to 52 hours with a mean of 35 hours. ' In adults, the mean serum 
26 
half-life is 33 hours. Thus, the only pediatric group that is ap-
preciably different from adults are infants. 
Total body clearance (Cl^) digoxin in these same populations 
shows similar diversity with values of 25 to 65 and 75 to 236 ml/min/ 
2 
1.73m in neonates and infants, respectively. These large ranges in 
th and CI, have been explained as a function of developmental changes b 
in renal glomerular function which alter renal clearance of digoxin 
27-29 
with increasing age. By four to six months of age, the total 
2 6 20 
body clearance rate approximates that of adults. ' ' 
Thus, on a pharmacokinetic basis, there appears to be little 
reason to dose digoxin any differently in children than in adults; 
that is, a once-a-day regimen instead of a twice-a-day regimen should 
be adequate. However, it is common practice to dose children every 
12 hours. 
STUDY OBJECTIVES 
There were two objectives to this study. The primary objective 
was to investigate if there was a significant difference in digoxin 
serum concentration obtained with once-a-day and twice-a-day digoxin 
administration regimens. This was done by comparing serum concentra-
tions of digoxin achieved by once-a-day and twice-a-day dosing. 
A secondary objective was to evaluate the relationship between 
serum and salivary concentrations of digoxin. 
MATERIALS AND METHODS 
Design 
The study used a crossover design with each patient serving as 
his or her own control. 
6 
Patient Population 
The population consisted of six outpatients from the Cardiology 
Clinic at Primary Children's Medical Center. The range of ages was 4 
to 19 years with a mean of 8.3. Three subjects were male and three 
were female, weighing between 13 and 53 kg with a mean weight of 26.4 
± 19.4 kg (Table 1). All patients were receiving oral digoxin on a 
twice-a-day schedule prior to entry into the study. Informed written 
consent was obtained from the parents of each patient judged to be 
suitable for entry into the study (Appendix A). 
Methods 
Parents kept daily records of times doses were given and exact 
pill counts were taken prior to and at the end of the study (Appendix 
B). 
Upon entering the study, serum and saliva samples were obtained 
from each patient eight hours after the last reported dose. All 
patients maintained their twice-a-day digoxin dosing schedule for a 
minimum of 14 days to assure that steady state serum concentrations 
had been attained. After this time period, serum and saliva samples 
were obtained eight hours after the last reported dose. Each patient 
was then scheduled to receive a single daily dose using the same total 
daily dose of digoxin. This schedule was maintained for a minimum of 
14 days with daily recording by the parents of specific times each 
dose was administered. At the end of the second study period, serum 
and saliva samples were again obtained eight hours after the last re-
ported dose. After the study, all patients were switched back to 
twice-a-day digoxin administration. 
Saliva samples (1 ml) were drawn in plastic syringes and then put 
into plastic freezing tubes and stored at -70°C. Blood samples, drawn 
® 
into silicone coated tubes (red top Vacutainers , Becton-Dickinson, 
Rutherford, N.J.) were centrifuged for five minutes at 2,500 RFM and the 
serum was removed and stored at -70°C, until they were assayed for 
digoxin concentration in the clinical laboratory of Primary Children's 
Medical Center. 
Digoxin Assay 
Each saliva sample was divided in half and the duplicate samples 
were extracted with 0.2 ml of chloroform (CHC13) by gentle shaking for 
ten minutes. After centrifugation, the aqueous phase was removed. 
Duplicate 0.8 ml aliquots of CHC13 extract were obtained and dried 
under air at 45°C. The dried CHCl^ extract was dissolved in 0.2 ml 
blank serum and assayed by radioimmunoassay for digoxin concentration 
along with the patients' serum. 
Digoxin concentrations were determined by the RIAphase Digoxin 
® 
Reagent System (Beckman Instruments, Inc., Berkely, California) de-
signed for the quantitative radioimmunoassay of digoxin as described 
30 
by Smith. The method's lowest level of sensitivity was 0.2 ng/ml. 
The percent difference between the standard curve and the actual 
readings ranged from -16.6 to +13.8 percent. 
125 
This procedure utilizes I labeled digoxin (I.D.) as the tracer 
and digoxin-specific antibodies capable of binding both unlabeled 
digoxin (U.D.) and I.D. After conventional incubation of antibody 
with serum and binding equilibration of I.D. and U.D. with antibody, 
the solution is passed through a chamber containing an excess of 
8 
immunoadsorbent bound to cellulose. The I.D. and U.D. not bound to 
antibody is bound in this chamber and the bound I.D. and U.D. passed 
out, where radioactivity is measured by a gamma counter. After a wash-
out of the immunoadsorbent chamber to determine the percent of I.D., 
the value is compared to a standard curve. 
STATISTICAL ANALYSIS 
The Wilcoxin matched-pairs signed-ranks test was used to 
determine if there was a statistically significant difference between 
digoxin serum concentration levels produced by the two dosage 
31 
schedules. Linear regression was used to evaluate the relationship 
between serum and saliva digoxin concentrations. 
RESULTS 
The patients' doses ranged from 4.7 to 12.2 mcg/kg/day with a mean 
of 8.9 ± 3.2 mcg/kg/day (Table 2). Results of the serum and saliva con-
centration determinations are presented in Tables 3 and 4. Changes in 
serum digoxin concentration produced by the different dosing regimens 
is illustrated in Figure 1. The intrapatient difference between the 
two dosing regimens (using digoxin concentrations from weeks two and 
four) did not show a statistically significant difference (T = 8, 
p > 0.05). The mean serum digoxin concentration (± standard deviation) 
of twice-a-day dosing was 0.63 ± 0.15, and of once-a-day dosing was 
0.76 ± 0.38 ng/ml. The range of the difference of serum digoxin be-
tween the two regimens ranged from -29 to +143 percent. 
Patient number 3 missed four appointments and his parents' com-
pliance and understanding of the study was questionable. This patient's 
9 
serum digoxin concentration was also much higher than expected. That 
could be due to the drug being administered at a time different than 
reported. Therefore the study data were also analzyed with the 
patient 3 data deleted. After excluding his data, the above calcula-
tions were performed again. Again the intrapatient difference between 
the two dosing regimens did not show a statistically significant 
difference (T = 7, p > 0.05) and the range of the difference of serum 
digoxin between the two regimens was -29 to +51 percent. None of the 
patients experienced any clinical signs of toxicity. 
Linear regression was performed to evaluate the relationship be-
tween the serum and saliva digoxin concentrations (Figure 2). The 
resultant correlation coefficient (r = 0.651) was significant (df = 
15, a < 0.005), the equation describing the best line is y = 0.612x + 
0.308, with variable x = saliva concentration, and variable y = serum 
concentrations. The range of the difference of digoxin concentration 
between serum and saliva ranges from -64 to +65 percent. Visual 
inspection of Figure 2 reveals considerable scatter, so that the use 
of this relationship may be unreliable. 
Compliance was judged with the assistance of the "patient's daily 
record" forms (Appendix B) and exact pill counts. According to these 
records all patients had 100 percent compliance except patient 1, whose 
compliance was 85 percent. However, as noted above, the compliance of 
patient 3 was questionable. 
DISCUSSION 
Digoxin is often used in the pediatric population. The literature 
provides conflicting information concerning the most appropriate dosing 
10 
regimen of digoxin in children.^ Data demonstrating an age dependent 
rate of digoxin elimination from the neonate period through childhood 
13 20 have been published by various researchers. Lang and Wettrell 
found that neonates have a digoxin elimination half-life between 20 and 
20 25 
60 hours. Wettrell and Dungan evaluated digoxin kinetics in infants 
6 13 
and found it to range from 15 to 33 hours. Singh and Lang found 
that children have a digoxin elimination half-life of 15 to 52 hours. 
On the basis of the long half-life, it seems reasonable to administer 
digoxin once daily in children. This is supported by our data which 
demonstrate no statistically significant difference between eight hour 
serum levels produced by the two dosing regimens. It should be noted, 
however, that intrapatient differences with the two dosing regimens 
were often large. While these differences were not clinically signi-
ficant according to clinical evaluation by a pediatric cardiologist, 
the possibility exists that toxicity or loss of therapeutic response 
could occur with such large changes. While some patients' digoxin 
concentrations were higher on the once-a-day schedule, others were 
lower. This may be due to interpatient differences in absorption 
rate, the length of the drug distribution phase or the interval 
between the blood draw and the administration of the last dose. It 
should also be noted that there was no clinical evidence of toxicity 
or loss of therapeutic response when the patients changed from one 
regimen to the other. 
Further, one may approximate maximum and minimum digoxin con-
centrations produced by the same dose given once-a-day or as two 
divided doses, using the relationships: 
11 
"Kel*t 
C = Dose . e 
P min z? — 
ss -K 1.t 
Vd(l - e 6 1 ) 
C = Dose p max — . r ss -K . t el Vd (1 - e ) 
where t = dosage interval, and using reported pharmacokinetic para-
meters for children, (Vd=9 1/kg, Kel=0.0198 hr - 1, Dose=3 mcg/kg/day). 
On a once-a-day digoxin regimen (t=24 hours), C , =0.54 ng/ml, 
p m m S s and C =0.86 ng/ml. With a twice-a-day digoxin regimen (t= p maxss 
12 hours), C . =0.62 ng/ml and C =0.78 ng/ml. There was P m* nss P m a x s s 
little difference between the digoxin serum concentration produced by 
the two dosing regimens. It is recognized that these equations 
assume I.V. bolus dosing and a one compartment open model, neither of 
which hold for orally administered digoxin. Nonetheless, the basic 
principles apply and are cogent to our argument. Thus we can see no 
basis for twice-a-day dosing in children. 
Performing the same calculations for infants as they comprise 
the only pediatric group with mean half-life different from that of 
adults, using K .. of 0.035 hr C , and C . , the values el p maxss p mxnSs 
for the once-a-day or twice-a-day regimen were 0.59 and 0.26 ng/ml, 
and 0.49 and 0.32 ng/ml, respectively. Once again we see little 
difference between the dosing regimens and no basis for twice-a-day 
dosing in infants or children. 
All parents stated that it was much easier to remember the once 
daily dose rather than the twice daily dose, the former regimen being 
more convenient. Our results suggest that it may be appropriate to 
recommend once daily dosing of digoxin, which will be more convenient 
and provide adequate serum concentrations. 
Huffman found an excellent linear correlation between serum and 
21 
saliva digoxin concentration (r = 0.988) but this finding was not 
23 
supported by Krivoy who reported the correlation coefficient to be 
22 
0.71, or by Buchanan who reported a correlation coefficient of 0.41. 
Our data analysis demonstrated a significant correlation of 0.651 
(p < 0.005) but too much scatter for this relationship to be used as 
a reliable clinical tool. The determination of saliva digoxin in 
children is easy and noninvasive, and appears to be an alternative to 
blood sampling, when blood sampling is difficult or not possible. Our 
findings did not demonstrate a consistent relationship, therefore the 
use of saliva in place of serum determinations cannot be recommended 
on a routine basis. 
CONCLUSIONS 
Pediatric patients in this study required higher doses on a 
mcg/kg basis than do adults to achieve plasma concentrations that 
are considered therapeutic in adults. There is no evidence that 
children are less sensitive to digoxin than are adults. Calculations 
performed on data from this study as well as theoretical data, showed 
that there was no statistically significant difference between a once-
a-day regimen and a twice-a-day regimen. Intrapatient differences, 
however, could be clinically important. 
The relationship between serum and saliva digoxin concentration 
was statistically significant, but showed considerable variation and 
cannot be recommended to replace serum concentration determinations 
based on the data obtained. 
SH19VI 
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TABLE 1. Characteristics of the Patient 
Age Weight 
Patient Sex (yrs) (kg) Diagnosis 
1 M 11 50.0 Tricuspid atresia with Glen 
Anastomosis and Blalock -
Taussig shunt 
2 F 19 53.0 Truncus arteriosus 
Eisenmenger Syndrome 
3 M 4 14.8 Tetralogy of fallot - repaired 
4 F 5 13.8 Subaortic stenosis - repaired 
with artificial mitral valve 
5 F 5 13.0 Single ventricle with pulmonary 
atresia, Blalock - Taussig 
shunt 
6 M 6 14.0 Single ventricle with pulmonary 
stenosis and Blalock - Taussig 
shunt 
16 
TABLE 2. Patients Digoxin Dosing Regimens 
Digoxin Dose Digoxin Dose 
Patient (mg) (mcg/kg/day) 
1 0.125 BID 5.0 
0.250 QD 
2 0.125 BID 4.7 
0.250 QD 
3 0.09 BID 12.2 
0.18 QD 
4 0.07 BID 10.1 
0.14 QD 
5 0.065 BID 10.0 
0.13 QD 
6 0.08 BID 11.4 
0.16 QD 
Mean ± Standard 
Deviation 
8.9 ± 3.2 
17 
TABLE 3. Patient's Serum Levels 
Serum % Difference 
Digoxin Digoxin of Serum 
Patient Regimen (ng/ml) Digoxin* 
1 BID < 0.15 
BID 0.51 
QD 0.36 - 29 
2 BID 0.75 
BID 0.56 
QD 0.59 + 5 
3 BID 0.29 
BID 0.56 
QD 1.36 +143 
4 BID 0.60 
BID 0.54 
QD 0.52 - 4 
5 BID 0.74 
BID 0.71 
QD 1.07 + 51 
6 BID 0.86 
BID 0.91 
QD 0.65 - 29 
Mean + 23 
% Difference of serum digoxin was calculated using the second figure 
of twice-a-day and once-a-day digoxin regimen. 
TABLE 4. Patient's Serum and Saliva Levels 
Serum Saliva % Difference 
Digoxin Digoxin between 
Patient (ng/ml) (ng/ml) Serum and Saliva 
1 < 0.15 < 0.15 
0.51 0.42 - 18 
0.36 0.33 - 8 
2 0.75 0.83 + 11 
0.56 0.57 + 2 
0.59 0.78 + 32 
3 0.29 0.25 - 14 
0.56 0.51 - 9 
1.36 1.32 - 3 
4 0.60 0.53 - 12 
0.54 0.89 + 65 
0.52 0.40 - 23 
5 0.74 0.56 - 24 
0.71 0.70 - 1 
1.07 0.38 - 64 
6 0.86 0.52 - 40 
0.91 0.98 + 8 
0.65 0.39 - 40 
Mean ± Standard 
Deviation 




Figure I. COMPARISON OF CHANGE IN SERUM 
DIGOXIN CONCENTRATION 
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Figure 2. RELATIONSHIP BETWEEN SALIVA AND 
SERUM DIGOXIN 
SERUM DIGOXIN (ng/ml) 
APPENDIXES 
APPENDIX A 
COMPARISON OF ONCE VS TWICE A DAY DIGOXIN DOSING 
Consent and agreement to participate as an experimental research 
subject in clinical research. 
Date 
Your childs' physician has prescribed a drug called digoxin for his or 
her heart disorder. It is the purpose of this research study, in which 
your childs' participation is invited, to determine whether it makes a 
difference if digoxin is given once or twice daily. The total daily 
dose would be the same in either case. We are also trying to determine 
the relationship between blood and salivary levels of digoxin. 
If your child participates he or she will continue to take digoxin on 
the present schedule (twice a day) for two weeks and will then take 
the total dose once a day for two weeks. Blood (less than one-half 
teaspoonful) and saliva samples will be collected on the first day of 
the study and at the end of each two week interval described above. 
The only risk of participation in this study is that of drawing blood 
(redness of vein and mild pain). There is no financial cost for 
part icipat ing. 
The potential benefit to your child is a simplified dosing schedule 
of digoxin and the free determination of digoxin levels. Participation 
is strictly voluntary. 
If you have any questions during the course of this study you may con-
tact Dr. Ruttenberg (581-7340) or Dr. Bosso (581-7545). 
In the event you sustain physical injury resulting from the research 
project in which you are participating, the University of Utah will 
provide you, without charge, emergency and temporary medical treatment 
not otherwise covered by insurance. Furthermore, if your injuries are 
caused by negligent acts or omissions of University employees acting in 
the course and scope of their employment, the University may be liable 
to limitations prescribed by law, for additional medical costs and 
other damages you sustain. If you believe that you have suffered a 
physical injury as a result of participating in this research program, 
please contact the Office of Research Administration, phone number 
581-6903. 
I acknowledge that I have had a fair opportunity to ask questions about 
the above procedures. I understand that I am free to withdraw my 
consent and to discontinue my child's participation in the project at 
any time without prejudice. I agree that data from these experiments 
may be used for medical and scientific purposes, including publica-
tions, with understanding that my child's identity will not be 
revealed unless I expressly consent thereto. 
Patient Name: 




Patient's Daily Record 
Date Began: 
Time of Dose 
Date A.M. P.M. Comments 
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College of Pharmacy 
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(801) 581-5941 
Date of Birth: December 28, 1950 
Place of Birth: Hadera, Israel 
Marital Status: Single 
Licensure: Registered Pharmacist, Israel - 1975 
Social Security 
Number: 990001886 
EDUCATION AND TRAINING 








Doctor of Pharmacy 
University of Utah 
Salt Lake City, UT 
1981-1983 
Residency in Clinical Pharmacy Practice 
University of Utah 
Salt Lake City, UT 
1981-1983 
UNIVERSITY HONORS 




Jerusalem, Israel - 1981 
Fund for Higher Education 
Tel Aviv, Israel - 1981 
American Association of University Women Educational 
Foundation 
Washington, DC - 1982 
TEACHING EXPERIENCE 
Teaching Assistant 
Physical Pharmacy for Third Year Pharmacy Students 
Hebrew University School of Pharmacy 
Jerusalem, Israel 
Autumn 1976, 1977 
Teaching Assistant 
Pharmaceutics for Second Year Pharmacy Students 
Hebrew University School of Pharmacy 
Jerusalem, Israel 
Spring 1977, 1978 
Teaching Fellow 
Adult Medicine, Pediatrics, Obstetrics and Gynecology, Drug 
Information, Ambulatory Care, Surgery, and Geriatric Clerkships 
Department of Pharmcy Practice 
College of Pharmacy 
University of Utah 
Fall 1981 - Spring 1983 
Responsibilities: Teach skills in patient monitoring, drug 
therapy selection, medication histories, 
and conduct pharmacy rounds 
PROFESSIONAL EXPERIENCE 
Pharmacy Intern 
Norsk Medicinal Depot 
Oslo, Norway 
June 1975 - December 1975 
Responsibilities: Compounding and dispensing of medications, 
production and quality control under the 
supervision of a registered pharmacist 
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PROFESSIONAL EXPERIENCE (continued) 
Registered Pharmacist 
State Support Health Maintenance Organization 
Jerusalem, Israel 
January 1976 - June 1976 
Responsibilities: Compounding and dispensing of medications, 
patient counseling 
Research Assistant 
School of Pharmacy 
Jerusalem, Israel 
July 1976 - December 1976 






July 1977 - June 1978 
Responsibilities: Pre and postsurgery patient care which 
included administering medication (oral 





July 1978 - June 1981 
Responsibilities: Patient drug histories, counseling, moni-
toring adverse drug reactions, chemo-
therapy admixtures, inservices to nurses 
and medical staff, Journal Club 
i 
Clinical Pharmacy Resident 
Department of Pharmacy Practice 
University Hospital 
University of Utah 
August 1981 - June 1983 
Adult Internal Medicine 18 weeks 
Ambulatory Care - Geriatrics 12 weeks 
General Pediatrics 6 weeks 
General Surgery 6 weeks 
Adult Infectious Disease 6 weeks 
Adult Cardiology 6 weeks 
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PROFESSIONAL EXPERIENCE (continued) 
Drug Information 6 weeks 
Obstetrics and Gynecology 6 weeks 
Psychiatry 6 weeks 
Hospital Pharmacy Management 3 weeks 
Burn Unit 3 weeks 
Pediatrics Hematology/Oncology . . . . 3 weeks 
Pediatrics Neurology 3 weeks 
(Medical team member, daily patient care rounds, monitoring 
patient therapy, performing medication histories, providing 
pharmacokinetic and drug therapy selection, inservice pre-
sentations, and pharmacy rounds) 
On-call clinical pharmacy (Drug Information Service, 
Toxicology Service, Cardiac Arrest Team) 
Clinical Pharmacy Seminars (to faculty members and hospital 
pharmacists at the University of Utah) 
Committee meetings (Institutional Review Board, Pharmacy and 
Therapeutics Committee) 
Research (see Research in Progress) 
RESEARCH AND OTHER CREATIVE WORK 
Principal Investigator: Clinical Pharmacists' Role in Improving 
Patient Compliance. Shimona Yoselsson-Superstine, Pharm.D., 
Michael Levy, M.D., October 1976-January 1978. 
Co-Investigator: A Comparative Analysis of Plasma Concen-
tration in Once-a-Day VS Twice-a-Day Digoxin Regimen in the 
Pediatric Patient. John A. Bosso, Pharm.D., Herbert Ruttenberg, 
M.D. - Funded by Burroughs Wellcome - $900. March 1982-present. 
ARTICLES IN REFEREED JOURNAL 
Yoselsson-Superstine S, Klieman R, Levy M: Clinical pharmacist's 
role in improving patient compliance. J Clin Pharm 1979; 4:53-57. 
MISCELLANEOUS PUBLICATIONS 
Klieman R: Transcutaneous nitroglycerin patches. Drugs in 
Patient Care (University of Utah Hospital) 1982; 5:6. 
Klieman R: Timolol: a non-selective beta-blocker for reducing 





"Amiodorone - A New Antiarrhythmic Agent" Presented to medical 
housestaff, University of Utah Medical Center, Salt Lake City, 
UT, May 1982. 
"Amrinone - A New Inotropic Agent" Presented to medical house-
staff, University of Utah Medical Center, Salt Lake City, 
UT, May 1982. 
"Renal Tubular Acidosis" Presented to medical housestaff, 
University of Utah Medical Center, Salt Lake City, UT, May 1982. 
INVITED LECTURES 
"Management of Pulmonary Tuberculosis" Presented to first year 
Doctor of Pharmacy Candidates, in Advanced Pharmacotherapeutics 
Course, College of Pharmacy, University of Utah, January 1983. 
"Management of Chronic Renal Failure" Presented to first year 
Doctor of Pharmacy Candidates, in Advanced Pharmacotherapeutics 
Course, College of Pharmacy, University of Utah, January 1983. 
PROFESSIONAL SOCIETY MEMBERSHIPS 
Israeli Society of Pharmacists 
January 1976 - June 1981 
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